JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howell, L. L.
Right arrow Articles by Wilcox, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howell, L. L.
Right arrow Articles by Wilcox, K. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*COCAINE

Vol. 298, Issue 1, 1-6, July 2001

The Dopamine Transporter and Cocaine Medication Development: Drug Self-Administration in Nonhuman Primates

Leonard L. Howell and Kristin M. Wilcox

Yerkes Regional Primate Research Center (L.L.H., K.M.W.), Department of Psychiatry and Behavioral Sciences (L.L.H.), and Department of Pharmacology (L.L.H.), Emory University, Atlanta, Georgia

Despite intensive medication development efforts, no effective pharmacotherapy for cocaine abuse has demonstrated efficacy for long-term use. Given the obvious importance of the dopamine transporter in the addictive properties of cocaine, the development and use of compounds that target the dopamine transporter represents a reasonable approach for the pharmacological treatment of cocaine abuse. The therapeutic approach of replacement or substitute agonist medication has been successful, as shown with methadone maintenance for heroin dependence and nicotine replacement for tobacco use. A number of preclinical studies with dopamine transporter inhibitors provide evidence that substitute agonists may be used effectively to reduce cocaine use. Nonhuman primate models of drug self-administration provide a rigorous, systematic approach to characterize medication effectiveness in subjects with a documented history of drug use. Several cocaine analogs and other dopamine transporter inhibitors, including analogs of GBR 12909 and WIN 35,065-2, have been shown to reduce cocaine self-administration in nonhuman primates. A possible limitation to the use of selective dopamine transporter inhibitors as medications is their potential for abuse liability given their demonstrated reinforcing effects in nonhuman primates. However, limited reinforcing properties in the context of treatment programs may be advantageous, contributing to improved patient compliance and enhanced medication effectiveness. Moreover, pharmacokinetic properties that result in slow onset and long duration of action may enhance their effectiveness to reduce cocaine use while limiting their abuse liability.

0022-3565/01/2981-0001$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
L. L. Howell, F. I. Carroll, J. R. Votaw, M. M. Goodman, and H. L. Kimmel
Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 757 - 765.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. C. Campbell, T. A. Kopajtic, A. H. Newman, and J. L. Katz
Assessment of the Influence of Histaminergic Actions on Cocaine-Like Effects of 3{alpha}-Diphenylmethoxytropane Analogs
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 631 - 640.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. W. Czoty, C. R. Ramanathan, N. H. Mutschler, A. Makriyannis, and J. Bergman
Drug Discrimination in Methamphetamine-Trained Monkeys: Effects of Monoamine Transporter Inhibitors
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 720 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. P. Lindsey, K. M. Wilcox, J. R. Votaw, M. M. Goodman, C. Plisson, F. I. Carroll, K. C. Rice, and L. L. Howell
Effects of Dopamine Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys: Relationship to Transporter Occupancy Determined by Positron Emission Tomography Neuroimaging
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 959 - 969.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. M. Kahlig, J. A. Javitch, and A. Galli
Amphetamine Regulation of Dopamine Transport: COMBINED MEASUREMENTS OF TRANSPORTER CURRENTS AND TRANSPORTER IMAGING SUPPORT THE ENDOCYTOSIS OF AN ACTIVE CARRIER
J. Biol. Chem., March 5, 2004; 279(10): 8966 - 8975.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Davis, J. R. Votaw, J. D. Bremner, M. G. Byas-Smith, T. L. Faber, R. J. Voll, J. M. Hoffman, S. T. Grafton, C. D. Kilts, and M. M. Goodman
Initial Human PET Imaging Studies with the Dopamine Transporter Ligand 18F-FECNT
J. Nucl. Med., June 1, 2003; 44(6): 855 - 861.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hasegawa, H. Kusuhara, H. Endou, and Y. Sugiyama
Contribution of Organic Anion Transporters to the Renal Uptake of Anionic Compounds and Nucleoside Derivatives in Rat
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1087 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Alters Vesicular Monoamine Transport and Prevents Methamphetamine-Induced Dopaminergic Deficits
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1181 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. A. Lile, D. Morgan, A. M. Birmingham, Z. Wang, W. L. Woolverton, H. M. L. Davies, and M. A. Nader
The Reinforcing Efficacy of the Dopamine Reuptake Inhibitor 2beta -Propanoyl-3beta -(4-tolyl)-tropane (PTT) as Measured by a Progressive-Ratio Schedule and a Choice Procedure in Rhesus Monkeys
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 640 - 648.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
W. L. Woolverton, R. Ranaldi, Z. Wang, G. A. Ordway, I. A. Paul, P. Petukhov, and A. Kozikowski
Reinforcing Strength of a Novel Dopamine Transporter Ligand: Pharmacodynamic and Pharmacokinetic Mechanisms
J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 211 - 217.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. J. Hansen and J. P. Balthasar
Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia
Blood, August 28, 2002; 100(6): 2087 - 2093.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Kato, K. Kuge, H. Kusuhara, P. J. Meier, and Y. Sugiyama
Gender Difference in the Urinary Excretion of Organic Anions in Rats
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 483 - 489.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. M. Schweri, H. M. Deutsch, A.T. Massey, and S. G. Holtzman
Biochemical and Behavioral Characterization of Novel Methylphenidate Analogs
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 527 - 535.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Hasegawa, H. Kusuhara, D. Sugiyama, K. Ito, S. Ueda, H. Endou, and Y. Sugiyama
Functional Involvement of Rat Organic Anion Transporter 3 (rOat3; Slc22a8) in the Renal Uptake of Organic Anions
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 746 - 753.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.